FDA Approves New Iohexol Vials - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Approves New Iohexol Vials

The approval includes additional 300 mg iodine/mL and 350 mg iodine/mL vial presentations.

  • By

  • Kathryn Wighton

  • July 17, 2026

  • 2 min

Share

Clinical Scorecard: FDA Approves New Iohexol Vials

At a Glance

CategoryDetail
ConditionIohexol Injection Approval
Key MechanismsImaging procedures via various administration routes
Target PopulationAdult and pediatric patients aged 2 weeks and older
Care SettingImaging procedures

Key Highlights

  • Approval includes iohexol injection 350 mg iodine/mL and 300 mg iodine/mL vials
  • Products to be launched in Q3 2026
  • First generic versions referencing OMNIPAQUE
  • Boxed warning for intrathecal administration risks
  • Portfolio expected to meet majority of US market demand

Guideline-Based Recommendations

Diagnosis

  • Indicated for intrathecal, intra-arterial, intravenous, oral, rectal, intraarticular, and body cavity imaging procedures

Management

  • Monitor for serious adverse reactions associated with incorrect iodine concentration

Monitoring & Follow-up

  • Observe for headache, nausea, back or neck pain, dizziness after intrathecal administration

Risks

  • Serious adverse reactions include death, convulsions, seizures, and acute renal failure

Patient & Prescribing Data

Adults and pediatric patients aged 2 weeks and older

Administration routes include intrathecal, intra-arterial, intravenous, oral, rectal, and body cavity

Clinical Best Practices

  • Ensure correct iodine concentration for intrathecal administration
  • Monitor patients for adverse reactions post-administration

Related Resources & Content

Original Source(s)

FDA Approves New Iohexol Vials

  • by Kathryn Wighton

  • July 17, 2026

Related Content

AI may aid segmental pulmonary embolism detection

Incidental pulmonary embolism detection increased following AI deployment on routine contrast-enhanced CT, with the clearest increase occurring in segmental emboli.

Ipsilateral reference may reduce THA fluoroscopy

Operative-time–adjusted findings favored the ipsilateral technique, while absolute fluoroscopy time and radiation exposure remained similar between approaches.

AI may predict focal GBM recurrence

Optical analysis of resection-margin tissue identified tumor infiltration as the strongest contributor to predictions of where glioblastoma later recurred.